(Dicyanomethylidene)propanedioic acid | 653575-63-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (Dicyanomethylidene)propanedioic acid
• 英文别名: 2-(dicyanomethylidene)propanedioic acid
• CAS: 653575-63-4
• 化学式: C₆H₂N₂O₄
• 分子量: 166.09
• InChiKey: LKOIXZIQZBMVPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  122
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] SOLUBLE GUANYLATE CYCLASE ACTIVATORS<br/>[FR] ACTIVATEURS SOLUBLES DE GUANYLATE CYCLASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015088886A1

  公开（公告）日：2015-06-18

  A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (" cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceuticall acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

  公式I的化合物或其药学上可接受的盐，能够调节人体对环鸟苷单磷酸（"cGMP"）的产生，并且通常适用于治疗和预防与扰乱的cGMP平衡相关的疾病。此外，本发明还涉及制备公式I的化合物或其药学上可接受的盐的方法，用于治疗和预防上述疾病，并为此目的制备药物，以及包含公式I的化合物或其药学上可接受的盐的药物制剂。
• [EN] SOLUBLE GUANYLATE CYCLASE ACTIVATORS<br/>[FR] ACTIVATEURS DE GUANYLATE CYCLASE SOLUBLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011149921A1

  公开（公告）日：2011-12-01

  A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ("cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof.

  一种化合物的化学式（I）：或其药学上可接受的盐，能够调节体内环鸟苷酸单磷酸（“cGMP”）的产生，并且通常适用于治疗和预防与扰乱的cGMP平衡相关的疾病。此外，本发明还涉及制备化合物的化学式I或其药学上可接受的盐的方法，用于治疗和预防上述疾病，并为此目的制备药物，以及包含化合物的药物制剂的制备。
• Compositions curable by in situ generation of cations
  申请人：LOCTITE CORPORATION

  公开号：EP0232076A2

  公开（公告）日：1987-08-12

  A two-part composition curable by contact of respec­tive parts with one another, comprising: a first part com­prising a cationically polymerizable material and a first latent curing component; and a second part comprising a cat­ionically polymerizable material and a second latent curing component which is reactive with the first component to form cations which are curingly effective for the resin. A pre­ferred class of cation species comprises carbenium ions de­rived from reaction of organic halide compounds, as the first component, with silver salts of non-nucleophilic an­ions, e.g., SbCl₆⁻, SbCl₃⁻, SbF₆⁻, AsF₆⁻, SnCl₅⁻, PF₆⁻, BF₄⁻, CF₃SO₃⁻ and ClO₄⁻, as the second component. The re­spective parts of the two-part composition may be applied to matable surfaces which then are contacted to effect rapid bonding cure of the composition.

  一种可通过各部分相互接触而固化的双组分组合物，包括：第一部分，由可阳离子聚合的材料和第一潜伏固化成分组成；第二部分，由可阳离子聚合的材料和第二潜伏固化成分组成，第二潜伏固化成分与第一部分反应形成对树脂具有固化效果的阳离子。一类优选的阳离子包括有机卤化物（如第一组分）与非亲核阴离子银盐（如 SbCl₆）反应生成的硒离子、SbCl₆-、SbCl₃-、SbF₆-、AsF₆-、SnCl₅-、PF₆-、BF₄-、CF₃SO₃- 和 ClO₄-。可将双组分组合物的各部分涂抹在可熟化的表面上，然后与这些表面接触，以实现组合物的快速粘合固化。
• SOLUBLE GUANYLATE CYCLASE ACTIVATORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2575473B1

  公开（公告）日：2016-01-20
• US4717440A
  申请人：——

  公开号：US4717440A

  公开（公告）日：1988-01-05